1248 related articles for article (PubMed ID: 19122170)
21. Effect of atorvastatin on LDL & hs-CRP in a selected Thai population.
Boonbaichaiyapruck S; Cheepudomwit S; Panjavenin P; Suthichaiyakul T; Moleelerkpoom W; Benjanuwatra T; Sukanandachai B; Buakhamsri A
J Med Assoc Thai; 2008 Aug; 91(8):1189-95. PubMed ID: 18788689
[TBL] [Abstract][Full Text] [Related]
22. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.
Baldassarre S; Scruel O; Deckelbaum RJ; Dupont IE; Ducobu J; Carpentier YA
Int J Cardiol; 2005 Oct; 104(3):338-45. PubMed ID: 16186066
[TBL] [Abstract][Full Text] [Related]
23. Does high-sensitivity C-reactive protein add prognostic value to the TIMI-Risk Score in individuals with non-ST elevation acute coronary syndromes?
Correia LC; Lima JC; Rocha MS; D'Oliveira Junior A; Péricles Esteves J
Clin Chim Acta; 2007 Jan; 375(1-2):124-8. PubMed ID: 16916502
[TBL] [Abstract][Full Text] [Related]
24. A multimarker risk stratification approach to non-ST elevation acute coronary syndrome: implications of troponin T, CRP, NT pro-BNP and fibrin D-dimer levels.
Tello-Montoliu A; Marín F; Roldán V; Mainar L; López MT; Sogorb F; Vicente V; Lip GY
J Intern Med; 2007 Dec; 262(6):651-8. PubMed ID: 17986200
[TBL] [Abstract][Full Text] [Related]
25. Apolipoprotein B100 is a better treatment target than calculated LDL and non-HDL cholesterol in statin-treated patients.
Soran H; France MW; Kwok S; Dissanayake S; Charlton-Menys V; Younis NN; Durrington PN
Ann Clin Biochem; 2011 Nov; 48(Pt 6):566-71. PubMed ID: 22006975
[TBL] [Abstract][Full Text] [Related]
26. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
27. Errors that result from using the TC/HDL C ratio rather than the apoB/apoA-I ratio to identify the lipoprotein-related risk of vascular disease.
Sniderman AD; Jungner I; Holme I; Aastveit A; Walldius G
J Intern Med; 2006 May; 259(5):455-61. PubMed ID: 16629851
[TBL] [Abstract][Full Text] [Related]
28. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial.
Olsson AG; Schwartz GG; Szarek M; Sasiela WJ; Ezekowitz MD; Ganz P; Oliver MF; Waters D; Zeiher A
Eur Heart J; 2005 May; 26(9):890-6. PubMed ID: 15764620
[TBL] [Abstract][Full Text] [Related]
29. Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein.
Kappelle PJ; Zwang L; Huisman MV; Banga JD; Sluiter WJ; Dallinga-Thie GM; Dullaart RP
Expert Opin Ther Targets; 2009 Jul; 13(7):743-51. PubMed ID: 19505224
[TBL] [Abstract][Full Text] [Related]
30. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
[TBL] [Abstract][Full Text] [Related]
31. Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials).
Brilakis ES; de Lemos JA; Cannon CP; Wiviott SD; Murphy SA; Morrow DA; Sabatine MS; Banerjee S; Blazing MA; Califf RM; Braunwald E
Am J Cardiol; 2008 Sep; 102(5):552-8. PubMed ID: 18721511
[TBL] [Abstract][Full Text] [Related]
32. Pregnancy-associated plasma protein-A elevation in patients with acute coronary syndrome and subsequent atorvastatin therapy.
Miedema MD; Conover CA; MacDonald H; Harrington SC; Oberg D; Wilson D; Henry TD; Schwartz RS
Am J Cardiol; 2008 Jan; 101(1):35-9. PubMed ID: 18157962
[TBL] [Abstract][Full Text] [Related]
33. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A;
J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114
[TBL] [Abstract][Full Text] [Related]
34. Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study.
Macin SM; Perna ER; Farías EF; Franciosi V; Cialzeta JR; Brizuela M; Medina F; Tajer C; Doval H; Badaracco R
Am Heart J; 2005 Mar; 149(3):451-7. PubMed ID: 15864233
[TBL] [Abstract][Full Text] [Related]
35. High-dose statin and COX-2 inhibitor therapy rapidly decreases C-reactive protein level in patients with unstable angina.
Chyrchel M; Dudek D; Bartuś S; Legutko J; Heba G; Dubiel JS
Kardiol Pol; 2004 Sep; 61(9):213-21; discussion 222-4. PubMed ID: 15531933
[TBL] [Abstract][Full Text] [Related]
36. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy.
Wiviott SD; Cannon CP; Morrow DA; Ray KK; Pfeffer MA; Braunwald E;
J Am Coll Cardiol; 2005 Oct; 46(8):1411-6. PubMed ID: 16226163
[TBL] [Abstract][Full Text] [Related]
37. Short-term effects of atorvastatin on C-reactive protein.
Riesen WF; Engler H; Risch M; Korte W; Noseda G
Eur Heart J; 2002 May; 23(10):794-9. PubMed ID: 12009719
[TBL] [Abstract][Full Text] [Related]
38. The pravastatin inflammation CRP evaluation (PRINCE): rationale and design.
Albert MA; Staggers J; Chew P; Ridker PM;
Am Heart J; 2001 Jun; 141(6):893-8. PubMed ID: 11376301
[TBL] [Abstract][Full Text] [Related]
39. Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study.
Kinlay S; Schwartz GG; Olsson AG; Rifai N; Szarek M; Waters DD; Libby P; Ganz P;
Arterioscler Thromb Vasc Biol; 2008 Jan; 28(1):142-7. PubMed ID: 17991875
[TBL] [Abstract][Full Text] [Related]
40. C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER).
Sattar N; Murray HM; McConnachie A; Blauw GJ; Bollen EL; Buckley BM; Cobbe SM; Ford I; Gaw A; Hyland M; Jukema JW; Kamper AM; Macfarlane PW; Murphy MB; Packard CJ; Perry IJ; Stott DJ; Sweeney BJ; Twomey C; Westendorp RG; Shepherd J;
Circulation; 2007 Feb; 115(8):981-9. PubMed ID: 17283264
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
